Franklin Resources
TAK icon

Franklin Resources’s Takeda Pharmaceutical TAK Stock Holding History

Franklin Resources’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$646K Buy
40,282
+14,265
+55% +$236K ﹤0.01% 2471
2026
Q1 		$482K Buy
26,017
+8,605
+49% +$151K ﹤0.01% 2480
2025
Q4 		$271K Sell
17,412
-2,046
-11% -$29.3K ﹤0.01% 2668
2025
Q3 		$285K Buy
19,458
+713
+4% +$10.6K ﹤0.01% 2685
2025
Q2 		$290K Buy
18,745
+1,953
+12% +$28.9K ﹤0.01% 2575
2025
Q1 		$250K Sell
16,792
-2,999
-15% -$42K ﹤0.01% 2567
2024
Q4 		$262K Buy
19,791
+2,763
+16% +$38K ﹤0.01% 2559
2024
Q3 		$244K Buy
+17,028
New +$242K ﹤0.01% 2564
2024
Q2 		– Sell
-185,572
Closed -$2.58M – 2967
2024
Q1 		$2.58M Buy
185,572
+57,020
+44% +$829K ﹤0.01% 1631
2023
Q4 		$1.83M Sell
128,552
-54,473
-30% -$773K ﹤0.01% 1418
2023
Q3 		$2.83M Buy
183,025
+45,244
+33% +$700K ﹤0.01% 1265
2023
Q2 		$2.16M Buy
137,781
+120,782
+711% +$1.98M ﹤0.01% 1389
2023
Q1 		$280K Buy
16,999
+3,745
+28% +$59.7K ﹤0.01% 1888
2022
Q4 		$207K Sell
13,254
-375
-3% -$5.24K ﹤0.01% 1994
2022
Q3 		$177K Buy
13,629
+3,572
+36% +$49.7K ﹤0.01% 2011
2022
Q2 		$142K Sell
10,057
-28,659
-74% -$409K ﹤0.01% 2092
2022
Q1 		$554K Sell
38,716
-2,740
-7% -$40.2K ﹤0.01% 1791
2021
Q4 		$565K Sell
41,456
-42,981
-51% -$603K ﹤0.01% 1862
2021
Q3 		$1.38M Sell
84,437
-174,525
-67% -$2.93M ﹤0.01% 1549
2021
Q2 		$4.36M Sell
258,962
-116,572
-31% -$1.98M ﹤0.01% 1169
2021
Q1 		$6.86M Buy
375,534
+52,837
+16% +$951K ﹤0.01% 1054
2020
Q4 		$5.87M Sell
322,697
-44,198
-12% -$775K ﹤0.01% 1065
2020
Q3 		$6.55M Sell
366,895
-57,255
-13% -$1.04M ﹤0.01% 991
2020
Q2 		$7.4M Sell
424,150
-58,207
-12% -$1.04M ﹤0.01% 933
2020
Q1 		$7.32M Buy
482,357
+60,176
+14% +$1.09M ﹤0.01% 854
2019
Q4 		$8.33M Sell
422,181
-163,197
-28% -$3.12M ﹤0.01% 922
2019
Q3 		$10M Sell
585,378
-21,452
-4% -$371K 0.01% 882
2019
Q2 		$10.7M Buy
606,830
+159,317
+36% +$2.9M 0.01% 874
2019
Q1 		$9.12M Buy
+447,513
New +$9.01M ﹤0.01% 901

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Franklin Resources's TAK Position: Q2 2026 in Review

Franklin Resources increased its Takeda Pharmaceutical (TAK) stake by 55% in Q2 2026, buying an estimated $236K and bringing the position to 40,282 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #2471.

Franklin Resources first reported a position in TAK in Q1 2019 and has held it in 29 quarters since. The position peaked at $10.7M in Q2 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Franklin Resources held 40,282 shares of Takeda Pharmaceutical worth $646K as of Q2 2026.
  • Franklin Resources bought 14,265 Takeda Pharmaceutical shares in Q2 2026, an estimated $236K.
  • Takeda Pharmaceutical made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2471 holding.
  • Franklin Resources first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 29 quarters since.
  • Franklin Resources's Takeda Pharmaceutical position peaked at $10.7M in Q2 2019.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.